De novo FGF12 mutation in 2 patients with neonatal-onset epilepsy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 16, 2016
- Accepted in final form September 29, 2016
- First Published November 10, 2016.
Author Disclosures
- Ilaria Guella, PhD,
- Linda Huh, MD,
- Marna B. McKenzie, BSc,
- Eric B. Toyota, BSc,
- E. Martina Bebin, MD,
- Michelle L. Thompson, PhD,
- Gregory M. Cooper, PhD,
- Daniel M. Evans, BSc,
- Sarah E. Buerki, MD,
- Shelin Adam, MSc,
- Margot I. Van Allen, MD, MSc,
- Tanya N. Nelson, PhD,
- Mary B. Connolly, MB,
- Matthew J. Farrer, PhD and
- Michelle Demos, MD
- Ilaria Guella, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Linda Huh, MD,
Non-profit - British Columbia Epilepsy Society Non-Profit - Matthew's Friends
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marna B. McKenzie, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric B. Toyota, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- E. Martina Bebin, MD,
1) Commercial-Novartis 2) Commercial- GW Pharmaceuticals, 3) FDA Orphan Drug Program-grant review, 4) NIH grant support- U01NS092595 PI for Phase IIb clinical trial, NIH #000426169, P20 NIH funded. Link#000427597, : Human Epilepsy Project- Sponsored by the Epilepsy Consortium NIH, ) NIH funded UM1HG007301, U54 NS092090-01
1) Commercial-Novartis 2) Commercial- GW Pharmaceuticals
1) Commercial- GW Pharmaceuticals
Pediatric Neurology- editorial board- 1 year
NONE
NONE
NONE
1) Commercial- GW Pharmaceuticals
1) Commercial- GW Pharmaceuticals
NONE
NONE
NONE
1) NIH grant support UM1HG007301-start date May 2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michelle L. Thompson, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory M. Cooper, PhD,
NONE
NONE
NONE
PLoS Genetics Genome Research
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NHGRI UM1HG007301
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel M. Evans, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarah E. Buerki, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shelin Adam, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Margot I. Van Allen, MD, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tanya N. Nelson, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
I am not employed by a commercial entity. My partner is employed by a commercial entity, but there is no relationship to this study.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I have no disclosure related to this study. I am a co- collaborator on a study funded by the BCCH Foundation and Genome BC.
NONE
NONE
NONE
NONE
NONE
NONE
- Mary B. Connolly, MB,
NONE
NONE
NONE
Associate Editor Canadian Journal of Neurological Sciences
NONE
NONE
NONE
NONE
Commercial Eisai talk on Lennox-Gastaut Syndrome Commercial Biocodex talk on Dravet syndrome
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew J. Farrer, PhD and
Michael J. Fox Foundation, SAB member since 2002 Parkinson's Society Canada, SAB member since 2011 EURAC, SAB member since 2013 Parkinson's UK, SAB member since 2014
NONE
NONE
Neurobiology of Disease, editorial board member, 2006- 2008 Parkinsonism & related disorders, editorial board member, 2008-present
Lrrk2 gene and mutations. a)International Publication Number WO 2006/045392 A2; (b) International Publication Number WO 2006/068492 A1; (c) US Patent Number 7,544,786; and (d) Norwegian patent 323175 -provisionally filed in 2004-2005
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Canadian Federal Government (CERC, CFI, CIHR)
NONE
Cunhill Foundation 2012-2016
NONE
NONE
Lundbeck Inc. ad Merck for Lrrk2 mouse models, 2016 Isis Pharma. for SNCA mouse model, 2015
NONE
NONE
NONE
- Michelle Demos, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Rare Disease Foundation microgrants 10-9 (June 2013) and 11-2 (December 2013)Alva Foundation (December 2014)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Centre for Applied Neurogenetics (CAN), Department of Medical Genetics (I.G., M.B.M., D.M.E., M.J.F.), Division of Neurology (L.H., E.B.T., S.E.B., M.B.C., M.D.), Department of Pediatrics, University of British Columbia and BC Children's Hospital, Vancouver, Canada; Department of Neurology (E.M.B.), University of Alabama at Birmingham; HudsonAlpha Institute for Biotechnology (M.L.T., G.M.C.), Huntsville, AL; Department of Medical Genetics (S.A., M.I.V.A.), University of British Columbia, Vancouver, Canada; and Departments of Pathology and Laboratory Medicine (T.N.N.), University of British Columbia and BC Children's Hospital, Vancouver, Canada.
- Correspondence to Dr. Demos: mdemos{at}cw.bc.ca
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Alert Me
Recommended articles
-
Article
Clinical spectrum of SCN2A mutations expanding to Ohtahara syndromeKazuyuki Nakamura, Mitsuhiro Kato, Hitoshi Osaka et al.Neurology, August 09, 2013 -
Article
Mutations in GABRB3From febrile seizures to epileptic encephalopathiesRikke S. Møller, Thomas V. Wuttke, Ingo Helbig et al.Neurology, January 04, 2017 -
Article
Extending the KCNQ2 encephalopathy spectrumClinical and neuroimaging findings in 17 patientsSarah Weckhuysen, Vanja Ivanovic, Rik Hendrickx et al.Neurology, October 09, 2013 -
Article
SCN2A encephalopathyA major cause of epilepsy of infancy with migrating focal seizuresKatherine B. Howell, Jacinta M. McMahon, Gemma L. Carvill et al.Neurology, August 19, 2015